Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 65   

Articles published

ARNA 4.34 -0.02 (-0.46%)
price chart
Is Arena The Next Alexion?
There was so much promise for the company and their recently approved drug Provenge that the valuation reached $6B for the company even before the product could hit the market. Many believers held the stock based on their ... Even though Alexion ...
Related articles »  
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Fights for Share of Weight-loss Pill ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA, ARNA message board) is expected to launch its patented Belviq treatment early next year, but there are some doubts that by that time Vivus, Inc. (NASDAQ:VVUS) will have made its Qsymia something of a ...
Related articles »  
Ampio's Promising Pipeline Could Send Company Higher
The following charts of Arena Pharmaceuticals (NASDAQ:ARNA), Amarin Corp (NASDAQ:AMRN) and Vivus, Inc. (NASDAQ:VVUS) show how rapidly prices can rise in the year before an approval.
Related articles »  
Anthera Pharmaceuticals Stock Rises After FDA Approves Development of ...
Arena Pharmaceuticals, Inc, Dendreon Corporation and Keryx Biopharmaceuticals are also among the hot stocks which was viewed my traders against Anthera Pharmaceutical.
Related articles »  
Heroes And Zeros: Arena Pharmaceuticals And Avanir Pharmaceuticals
Arena Pharmaceuticals is a clinical stage biopharmaceutical company that has discovered, developed, and moved the first anti-obesity drug through FDA approval in the last 13 years in June of 2012.
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug
In addition, Arena comes with some enticing benefits for a pharmaceutical suitor - 10 year Swiss Tax Haven and R&D Write-offs.
Related articles »  
Obesity Drugs Gain Attention on FDA Backing for Therapies
Third Rock Ventures is an early backer of Zafgen Inc., a biotechnology company in mid-stage trials of a therapy to treat obesity. The Food and Drug Administration cleared Belviq, from Arena Pharmaceuticals Inc. and Eisai Co., in June and Vivus Inc.'s ...
Vivus Shares Feel The Pain: Blockbuster Diet Drug Likely Won't Be Sold ...  Forbes
All Eyes On Vivus As Weight Loss Drug Hits Market  YCharts
Related articles »  
The Rev. Sun Myung Moon to be laid to rest in South Korea
Up to 30,000 people are expected to gather in Cheongpyeong, South Korea, on Saturday for the funeral of the Rev. Sun Myung Moon, the controversial founder of the Unification Church who died this month.
Related articles »  
Dr. Jean-Paul Castaigne, CEO of Angiochem
Yet the most exciting developments for Angiochem this year have been in the rare-diseases arena. The company raised its profile and brought publicity to its preclinical efforts in transporting enzyme drugs for orphan disorders into the brain in ...
UNC spinoff raises money for Alzheimer's drug research
Previously called Longo Pharmaceuticals, the company, which lists a Raleigh address but primarily operates out of San Francisco, aims to treat disorders of the Central Nervous System, particularly Alzheimer's, a degenerative disease that stands as the ...